Form 4: Stoke Therapeutics Director Sells Shares Under 10b5-1 Plan

Stoke Therapeutics Director Edward M. Kaye, MD, sold 42,461 shares of common stock for approximately $1.06 million under a pre-arranged 10b5-1 trading plan.

Summary

• Edward M. Kaye, MD, a Director of Stoke Therapeutics, Inc. (STOK), disposed of 42,461 shares of common stock.
• The transaction occurred on October 3, 2025, at a weighted average price of $25.0867 per share.
• The total value of the shares sold is approximately $1,065,100.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Dr. Kaye on December 30, 2024.
• Following this transaction, Dr. Kaye directly beneficially owns 49,124 shares of Stoke Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While a director selling shares can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates the negative impact, suggesting it's a planned liquidity event rather than a reaction to adverse company news.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• A director selling a significant number of shares could be perceived negatively by investors, potentially signaling a lack of confidence, even if pre-planned.

Risks

• Potential negative investor sentiment due to a director's share sale, which could put downward pressure on the stock price.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it pertains solely to an insider transaction.

Industry Context

This filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitors. Insider sales, even pre-planned, are routinely monitored by investors for potential signals regarding management's perception of future company performance or valuation within the biotechnology sector.

Comparison to Industry Standards

• This Form 4 filing details a personal stock transaction by a director and does not contain information that allows for a direct comparison to industry-wide financial benchmarks or specific comparable companies' operational results. The execution of a Rule 10b5-1 plan is a standard practice for insiders to manage their equity holdings while complying with insider trading regulations.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to minor short-term price fluctuations, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• No specific future actions, events, or milestones were mentioned in this filing, as it reports a past insider transaction.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-arranged 10b5-1 plan. While a director selling shares can sometimes be a negative signal, the pre-planned nature reduces its significance as an indicator of future company performance. Without additional information on the company's fundamentals or market conditions, this single transaction does not warrant a change from a 'hold' position.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Director Sale, Equity Transaction, 10b5-1 Plan, Edward M. Kaye